We are live on ! Find out more
APM

Avidity Partners Management Portfolio holdings

AUM $936M
1-Year Est. Return 195%
This Fund
S&P 500
This Quarter Est. Return
+54.86%
1 Year Est. Return
+195%
3 Year Est. Return
+460.87%
5 Year Est. Return
+815.5%
10 Year Est. Return
–
AUM
$1.56B
AUM Growth
+$837M
Cap. Flow
+$592M
Cap. Flow %
37.97%
Top 10 Hldgs %
44.99%
Holding
85
New
33
Increased
20
Reduced
4
Closed
28

Top Buys

Rank Stock Value
1
ABBV icon
AbbVie
ABBV
+$94.1M
2
BAX icon
Baxter International
BAX
+$69.8M
3
REGN icon
Regeneron Pharmaceuticals
REGN
+$46.6M
4
ARVN icon
Arvinas
ARVN
+$45.7M
5
IMMU
Immunomedics Inc
IMMU
+$41.5M

Top Sells

Rank Stock Value
1
SGEN
Seagen Inc. Common Stock
SGEN
+$49.1M
2
MRK icon
Merck
MRK
+$37.9M
3
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$25.5M
4
CAH icon
Cardinal Health
CAH
+$24.2M
5
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$22.7M

Sector Composition

Rank Sector Weight
1 Healthcare 91.95%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
RNAM
51
DELISTED
Avidity Biosciences
RNAM
$6.64M 0.43%
+234,814
New +$6.77M
TVTX icon
52
Travere Therapeutics
TVTX
$5.2B
$5.1M 0.33%
+250,000
New +$3.98M
LEGN icon
53
Legend Biotech
LEGN
$3.67B
$4.26M 0.27%
+100,000
New +$3.91M
AVDL
54
DELISTED
Avadel Pharmaceuticals
AVDL
$3.7M 0.24%
457,951
+75,951
+20% +$670K
FUSN
55
DELISTED
Fusion Pharmaceuticals Inc. Common Shares
FUSN
$2.88M 0.18%
+164,554
New +$2.87M
ZGNX
56
DELISTED
Zogenix, Inc.
ZGNX
$2.64M 0.17%
+97,870
New +$2.7M
BIOR
57
DELISTED
Biora Therapeutics, Inc. Common Stock
BIOR
$2.15M 0.14%
+955
New +$2.6M
ACAD icon
58
Acadia Pharmaceuticals
ACAD
$4.45B
– –
-357,000
Closed -$15.1M
AMRN
59
CALL
Amarin Corp
AMRN
$291M
– –
-81,240
Closed -$6.5M
BIIB icon
60
Biogen
BIIB
$30.1B
– –
-62,000
Closed -$19.6M
BMRN icon
61
BioMarin Pharmaceuticals
BMRN
$12B
– –
-302,000
Closed -$25.5M
CAH icon
62
Cardinal Health
CAH
$54.6B
– –
-505,000
Closed -$24.2M
CI icon
63
Cigna
CI
$80.1B
– –
-65,000
Closed -$11.5M
COLL icon
64
Collegium Pharmaceutical
COLL
$1.16B
– –
-17,000
Closed -$278K
CRL icon
65
Charles River Laboratories
CRL
$11.4B
– –
-57,000
Closed -$7.19M
CVS icon
66
CVS Health
CVS
$139B
– –
-277,000
Closed -$16.4M
GILD icon
67
Gilead Sciences
GILD
$167B
– –
-200,000
Closed -$15M
HUM icon
68
Humana
HUM
$46.6B
– –
-33,000
Closed -$10.4M
IRWD icon
69
Ironwood Pharmaceuticals
IRWD
$635M
– –
-735,000
Closed -$7.42M
LGND icon
70
Ligand Pharmaceuticals
LGND
$5.95B
– –
-163,506
Closed -$7.42M
MRK icon
71
Merck
MRK
$325B
– –
-515,616
Closed -$37.9M
MRNA icon
72
Moderna
MRNA
$21.9B
– –
-365,000
Closed -$10.9M
NERV icon
73
CALL
Minerva Neurosciences
NERV
$198M
– –
-123,750
Closed -$5.96M
NERV icon
74
Minerva Neurosciences
NERV
$198M
– –
-55,525
Closed -$2.67M
QURE icon
75
uniQure
QURE
$2.44B
– –
-237,000
Closed -$11.2M
1 2
3
4

Similar funds

NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
PWAM
Private Wealth Asset Management Cedar Rapids, Iowa $935M AUM 17.66% 1-Year Est. Return
LJAC
L.J. Altfest & Co New York $935M AUM 27.19% 1-Year Est. Return
NI
NetEase Inc Hangzhou, China $934M AUM 11.31% 1-Year Est. Return
MCM
Massar Capital Management Stamford, Connecticut $934M AUM 14.18% 1-Year Est. Return
TS
Tamar Securities Woodland Hills, California $934M AUM 26.74% 1-Year Est. Return
TW
TritonPoint Wealth Chevy Chase, Maryland $934M AUM 23.95% 1-Year Est. Return
PGA
Portland Global Advisors Portland, Maine $938M AUM 13.22% 1-Year Est. Return

Avidity Partners Management's Q2 2020 Portfolio in Review

As of Q2 2020, Avidity Partners Management held 85 positions worth $1.56B, up 116% from $724M the previous quarter. Its ten largest holdings account for 45% of the portfolio.

Avidity Partners Management deployed $592M of net new capital in Q2 2020, opening 33 new positions and adding to 20 existing holdings. Its largest new stake was Baxter International: 800,900 shares worth $69M.

By sector, the portfolio is most concentrated in Healthcare at 92% of assets, down from 92% a quarter earlier.

On the sell side, the largest reduction was Seagen Inc. Common Stock, an estimated $49.1M trimmed.

  • Avidity Partners Management's largest Q2 2020 buy was Baxter International: 800,900 shares worth $69M.
  • Avidity Partners Management added most to AbbVie in Q2 2020, an estimated $94.1M increase.
  • Avidity Partners Management's biggest Q2 2020 reduction was Seagen Inc. Common Stock, cutting an estimated $49.1M.
  • Avidity Partners Management fully exited Merck in Q2 2020, selling an estimated $37.9M.
  • Avidity Partners Management's ten largest holdings make up 45% of its $1.56B portfolio in Q2 2020.
  • Avidity Partners Management opened 33 new positions and closed 28 in Q2 2020.
  • Avidity Partners Management's portfolio value rose 116% quarter-over-quarter to $1.56B.

Based on Avidity Partners Management's 13F filing for Q2 2020, filed 14 Aug 2020.